Bayer wins priority review for CKD program finerenone after PhIII data showed a delay in disease progression
Less than three months after Bayer released positive Phase III data for a top program, the FDA has agreed to take up its case.
Regulators have granted priority review for finerenone, an experimental drug in patients with chronic kidney disease and type 2 diabetes, Bayer announced Tuesday. Bayer did not unveil an expected PDUFA date but noted the FDA would likely give finerenone a typical six-month look-over.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.